What will be Dr. Feldman's message on the 17th?
Her title is transplantation in the ALS trial
She has given years of her life to this work. Surely she must have something positive to say about the ongoing NSI-588 tial.
MHO and hope.
With regard to the SP, I think $1.50 derisks CUR substantially.The stroke and dementia trials have that much promise alone, even with a negative outcome in the ALS trial.
Low volume trading of recent weeks indicates to me that institutions - who according to Yahoo own about 30% of Neuralstem - are NOT selling. Smith on Stocks is not selling. Insiders are not selling. And neither am I !!!!
We have four bites at the Clinical Apple. Not many small bios can say that.
Look at it this way:
No news can wear us longs down. But in a way, no news is good because it gives CUR the time required to proceed with it's ongoing trials and it's research. The company has four ongoing trials, so we have four bites at theapple. In addition there is Dr. Feldman and her associates, all talented scientists. And as a bonus there is the promising work in Alzheimer disease on rats. Go CUR!
Dr Feldman must have good reason to stick with this drug,. and to work further to define its; efficacy. This ALS trial is is her like's work. Until she loses hope. I will hold on to CUR. Even if the ALS trail fails, the other tirals are well worth the share price, The smart move today id to hold tight IMO.